COVID-19 as an Aggravator of Cardiovascular Diseases: Increasing Immunoglobulin G, a Valuable Prognostic Factor for Heart Failure

IF 0.5 4区 医学 Q4 MICROBIOLOGY Jundishapur Journal of Microbiology Pub Date : 2023-09-13 DOI:10.5812/jjm-139233
Ali Tahan, Najmaldin Saki, Shirin Azizidoost, Farid Yousefi, Habib Haybar
{"title":"COVID-19 as an Aggravator of Cardiovascular Diseases: Increasing Immunoglobulin G, a Valuable Prognostic Factor for Heart Failure","authors":"Ali Tahan, Najmaldin Saki, Shirin Azizidoost, Farid Yousefi, Habib Haybar","doi":"10.5812/jjm-139233","DOIUrl":null,"url":null,"abstract":"Background: COVID-19 might worsen preexisting cardiac conditions and cause new heart failure (HF). To appropriately triage and treat patients, an early diagnosis is necessary. Objectives: This study assessed the levels of antibodies immunoglobulin G (IgG) and immunoglobulin M (IgM) required for the coronavirus spike S protein in the serum of individuals with cardiovascular disease (CVD) who developed HF complications from COVID-19. Methods: A total of 104 hospitalized patients with confirmed COVID-19 were equally divided into severe COVID-19 cases with new HF evidence and controls. The levels of IgG and IgM antibodies vs SARS-CoV-2 were measured. The possible correlation of antibody levels with underlying cardiac risk factors was also investigated. Results: It was found that 86% of HF patients and 5% of controls had an IgG level greater than 100 AU/mL (P < 0.05). Ischemic heart disease (IHD) was the most common disease in the patient group, and the highest level of antibodies was also found in this group. Conclusions: Increasing IgG during COVID-19 can be one of the signs of worsening heart disease, which is more prevalent in patients with an underlying IHD and hypertension.","PeriodicalId":17803,"journal":{"name":"Jundishapur Journal of Microbiology","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jundishapur Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/jjm-139233","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 might worsen preexisting cardiac conditions and cause new heart failure (HF). To appropriately triage and treat patients, an early diagnosis is necessary. Objectives: This study assessed the levels of antibodies immunoglobulin G (IgG) and immunoglobulin M (IgM) required for the coronavirus spike S protein in the serum of individuals with cardiovascular disease (CVD) who developed HF complications from COVID-19. Methods: A total of 104 hospitalized patients with confirmed COVID-19 were equally divided into severe COVID-19 cases with new HF evidence and controls. The levels of IgG and IgM antibodies vs SARS-CoV-2 were measured. The possible correlation of antibody levels with underlying cardiac risk factors was also investigated. Results: It was found that 86% of HF patients and 5% of controls had an IgG level greater than 100 AU/mL (P < 0.05). Ischemic heart disease (IHD) was the most common disease in the patient group, and the highest level of antibodies was also found in this group. Conclusions: Increasing IgG during COVID-19 can be one of the signs of worsening heart disease, which is more prevalent in patients with an underlying IHD and hypertension.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19加重心血管疾病:增加免疫球蛋白G,心衰的一个有价值的预后因素
背景:COVID-19可能会加重已有的心脏疾病并导致新的心力衰竭(HF)。为了对病人进行适当的分诊和治疗,早期诊断是必要的。目的:本研究评估了COVID-19并发心衰并发症的心血管疾病(CVD)患者血清中冠状病毒刺突S蛋白所需的抗体免疫球蛋白G (IgG)和免疫球蛋白M (IgM)水平。方法:将104例新冠肺炎确诊住院患者平均分为新发HF证据的重症病例和对照组。检测抗SARS-CoV-2的IgG和IgM抗体水平。抗体水平与潜在心脏危险因素的可能相关性也被调查。结果:86%的HF患者和5%的对照组IgG水平大于100 AU/mL (P <0.05)。缺血性心脏病(IHD)是患者组中最常见的疾病,抗体水平也最高。结论:COVID-19期间IgG升高可能是心脏病恶化的迹象之一,这在潜在IHD和高血压患者中更为普遍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
56
审稿时长
6-12 weeks
期刊介绍: Jundishapur Journal of Microbiology, (JJM) is the official scientific Monthly publication of Ahvaz Jundishapur University of Medical Sciences. JJM is dedicated to the publication of manuscripts on topics concerning all aspects of microbiology. The topics include medical, veterinary and environmental microbiology, molecular investigations and infectious diseases. Aspects of immunology and epidemiology of infectious diseases are also considered.
期刊最新文献
A Perspective Study on Therapeutic Drug Monitoring of Voriconazole in Pediatric Patients with Hematologic Disorders Genomic Characterization and Antimicrobial Resistance of Four Mcr-1 Escherichia coli Strains Isolated from Human and Environment Sources, Hainan Province, Tropical China IP-10, MIP1α, IL-6, and IL-1β as Biomarkers Associated with Disease Severity of COVID-19 Efficacy of Crude Extract from Streptomyces cellulosae Against Biofilm-Related Genes of Candida albicans Multiple-Locus Variable-Number Tandem Repeat Analysis Genotyping of Biofilm-Producing Pseudomonas aeruginosa Clinical Isolates
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1